Exercises of stock acquisition rights occurred during the target month. Delivered shares: 1,624,500 shares; number of rights exercised: 16,245 rights (4.7% of total issued). As of the end of October 2026, unexercised rights totaled 345,000 rights (34,500,000 shares), and remaining unexercised shares were 328,755 rights (32,875,500 shares). Monthly exercise rate: 1.2%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4594","jir_company_name":"BrightPath Biotherapeutics Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4594-20261102-01.pdf","jir_short_summary":"Exercises of stock acquisition rights occurred during the target month. Delivered shares: 1,624,500 shares; number of rights exercised: 16,245 rights (4.7% of total issued). As of the end of October 2026, unexercised rights totaled 345,000 rights (34,500,000 shares), and remaining unexercised shares were 328,755 rights (32,875,500 shares). Monthly exercise rate: 1.2%.","jir_summary":"### Key Points of the News\nPublished the monthly exercise status of the 21st stock acquisition rights allocated to a third party. In October, a total of 1,624,500 shares were delivered, 16,245 rights were exercised, and the exercise rate relative to the total issued stock acquisition rights was 1.2%.\n\n### Market Impact and Outlook\nUnexercised stock acquisition rights total 345,000 rights (34,500,000 shares), and remaining unexercised shares amount to 328,755 rights (32,875,500 shares), indicating limited dilution progression. It is necessary to monitor exercise trends in future monthly releases.","jir_financial_highlights":"Delivered shares (shares): 1,624,500 shares (Unknown)\nNumber of stock acquisition rights exercised (rights): 16,245 rights (Unknown)\nExercise rate relative to total issued: 1.2% (Unknown)","jir_category":"","jir_hashtags":"#BrightPathBiotherapeutics, #StockAcquisitionRights, #StockOptions","jir_key_figures":"Delivered shares: 1,624,500 shares\nNumber of stock acquisition rights exercised: 16,245 rights\nExercise rate: 1.2%","jir_meta_title":"BrightPath Biotherapeutics Co., Ltd. | Monthly Stock Acquisition Rights Exercise Status\uff5cOctober 2026","jir_meta_description":"Monthly exercise status of the 21st stock acquisition rights allocated to a third party by BrightPath Biotherapeutics Co., Ltd. Delivered shares: 1,624,500 shares; rights exercised: 16,245 rights; exercise rate: 1.2%; unexercised rights: 345,000 rights; remaining unexercised rights: 328,755 rights.","jir_og_title":"BrightPath Biotherapeutics Co., Ltd. | Monthly Exercise Status of Stock Acquisition Rights","jir_og_description":"Disclosure of the monthly exercise status of stock acquisition rights. Delivered shares: 1,624,500 shares; exercise rate relative to total issued: 1.2%. Unexercised rights: 345,000 rights; remaining unexercised shares: 32,875,500 shares.","jir_og_image_url":"\/assets\/og\/company-tender_offer.jpg","jir_chart_data_collection":"[]","ir_related_company":59787,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-140090","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n